Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

The primary end point, major pathologic response (MPR), was reviewed per consensus criteria and centrally confirmed: In the monotherapy arm, the MPR rate was 33.3%, with all responses being pathologic ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C ...

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and ...

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard ...